BIOMAT Database Logo BIOMAT Database Logo

[Pharmacokinetic, bacteriological and clinical studies on cefozopran in neonates]. 1997

T Abe, and M Sugiura, and Y Nakazato, and S Hashira, and K Yoshimura, and Y Kondoh, and Y Kawaoi, and T Tajima, and S Nagai, and N Funamoto, and S Sugimori, and S Nishimura
Department of Pediatrics, School of Medicine, Teikyo University.

Cefozopran (CZOP) was administered to nine newborn patients with infections at a dose of 20 mg/kg twice or three times daily for 5 to 6 days to evaluate the efficacy, safety and pharmacokinetics of cefozopran. 1. Blood concentrations CZOP was intravenously given to 6 newborn patients by drip infusion at a dose of 20 mg/kg over 30 minutes. The maximum blood concentrations (Cmax) were 38.4 micrograms/ml in a patient aged 0 day, 37.7 and 54.3 micrograms/ml in two patients aged 1 day, 51.3 and 64.1 micrograms/ml in two patients aged 3 days and 51.0 micrograms/ml in a patient aged 5 days. Cmax was lower in the patient aged 0 day. The elimination half life (T 1/2) was 9.2 hours in the patient aged 0 day, 4.9 and 3.7 hours in the patients aged 1 day, 3.1 and 2.4 hours in the patients aged 3 days and 2.9 in the patient aged 5 days, showing a prolongation of T 1/2 in patients of lower age. 2. Urinary excretion Of the 6 patients given CZOP at a dose of 20 mg/kg by intravenous drip infusion over 30 minutes, urine was collected in 5 patients. The cumulative excretion rate within 6 hours after infusion was as low as 19.8% of dose in the patient aged 0 day. The rates were elevated as high as 46.3 and 57.0% of dose in the patients aged 1 day. In the patient aged 3 days, the recovery within 4 hours after infusion was 47.3%. It was 70.6% of dose within 6 hours after dosing in the patient aged 5 days. The urinary recovery within 6 hours after dosing increased with the advance of age. 3. Clinical results Efficacy was evaluable in 7 patients. Of them, 3 had suspected septicemia, 2 pneumonia, 1 intrauterine infection and 1 urinary tract infection. The clinical efficacy was judged "excellent" in all the evaluable patients. Neither adverse drug reactions of signs and symptoms nor abnormal alterations of the laboratory test values were recognized in the 9 patients evaluable for safety. These results suggest that CZOP is an effective and safe drug for treatment of infections in the newborns. As for the dosage and method of administration from the view of the pharmacokinetic data obtained, intravenous drip infusion of 20 mg/kg once or twice daily was considered to be sufficient for patients aged 0 day. For patients aged 1 to 7 days and those aged 8 days or elder, the administration of twice to 3 times daily and 3 to 4 times daily were considered to be sufficient, respectively.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000097586 Cefozopran A fourth-generation cephalosporin antibacterial agent with a broad spectrum of activity against Gram-positive and Gram-negative bacteria. Cefozopran has a 1-methyltetrazolethiol (MTT) moiety at C-3 of its cephalosporin core. Cefozopran (CZOP),Cefozopran HCL,Cefozopran Hydrochloride,SCE 2787,SCE-2787,2787, SCE,HCL, Cefozopran,Hydrochloride, Cefozopran,SCE2787
D001424 Bacterial Infections Infections by bacteria, general or unspecified. Bacterial Disease,Bacterial Infection,Infection, Bacterial,Infections, Bacterial,Bacterial Diseases

Related Publications

T Abe, and M Sugiura, and Y Nakazato, and S Hashira, and K Yoshimura, and Y Kondoh, and Y Kawaoi, and T Tajima, and S Nagai, and N Funamoto, and S Sugimori, and S Nishimura
[Pharmacokinetic, bacteriological and clinical studies on cefozopran in neonates].
December 1997, The Japanese journal of antibiotics,
T Abe, and M Sugiura, and Y Nakazato, and S Hashira, and K Yoshimura, and Y Kondoh, and Y Kawaoi, and T Tajima, and S Nagai, and N Funamoto, and S Sugimori, and S Nishimura
[Pharmacokinetic, bacteriological and clinical studies on cefozopran in children].
November 1994, The Japanese journal of antibiotics,
T Abe, and M Sugiura, and Y Nakazato, and S Hashira, and K Yoshimura, and Y Kondoh, and Y Kawaoi, and T Tajima, and S Nagai, and N Funamoto, and S Sugimori, and S Nishimura
[Pharmacokinetic, bacteriological and clinical studies on cefozopran in the pediatric field].
November 1994, The Japanese journal of antibiotics,
T Abe, and M Sugiura, and Y Nakazato, and S Hashira, and K Yoshimura, and Y Kondoh, and Y Kawaoi, and T Tajima, and S Nagai, and N Funamoto, and S Sugimori, and S Nishimura
[Pharmacokinetic, bacteriological and clinical studies on aztreonam in neonates].
March 1990, The Japanese journal of antibiotics,
T Abe, and M Sugiura, and Y Nakazato, and S Hashira, and K Yoshimura, and Y Kondoh, and Y Kawaoi, and T Tajima, and S Nagai, and N Funamoto, and S Sugimori, and S Nishimura
[Bacteriological and clinical studies on cefozopran in pediatric field].
November 1994, The Japanese journal of antibiotics,
T Abe, and M Sugiura, and Y Nakazato, and S Hashira, and K Yoshimura, and Y Kondoh, and Y Kawaoi, and T Tajima, and S Nagai, and N Funamoto, and S Sugimori, and S Nishimura
[Pharmacokinetic and clinical studies on cefozopran in pediatrics].
November 1994, The Japanese journal of antibiotics,
T Abe, and M Sugiura, and Y Nakazato, and S Hashira, and K Yoshimura, and Y Kondoh, and Y Kawaoi, and T Tajima, and S Nagai, and N Funamoto, and S Sugimori, and S Nishimura
[Pharmacokinetic, bacteriological and clinical studies of ceftizoxime in neonates].
August 1988, The Japanese journal of antibiotics,
T Abe, and M Sugiura, and Y Nakazato, and S Hashira, and K Yoshimura, and Y Kondoh, and Y Kawaoi, and T Tajima, and S Nagai, and N Funamoto, and S Sugimori, and S Nishimura
[Pharmacokinetic, bacteriological and clinical studies on imipenem/cilastatin sodium in neonates].
May 1989, The Japanese journal of antibiotics,
T Abe, and M Sugiura, and Y Nakazato, and S Hashira, and K Yoshimura, and Y Kondoh, and Y Kawaoi, and T Tajima, and S Nagai, and N Funamoto, and S Sugimori, and S Nishimura
[Pharmacokinetic, bacteriological and clinical studies on imipenem/cilastatin sodium in neonates].
May 1989, The Japanese journal of antibiotics,
T Abe, and M Sugiura, and Y Nakazato, and S Hashira, and K Yoshimura, and Y Kondoh, and Y Kawaoi, and T Tajima, and S Nagai, and N Funamoto, and S Sugimori, and S Nishimura
[Pharmacokinetic and clinical studies on cefozopran in the field of pediatrics].
November 1994, The Japanese journal of antibiotics,
Copied contents to your clipboard!